Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
GLP-1RAs: Mechanism of Action and Role in HFpEF Management
Author(s): Magdy Abdelhamid , Mostafa M Abdrabou , Emanuel Faris , et al Added: 2 weeks ago

Heart Failure
GLP-1RA in Different HFpEF Phenotypes
Author(s): Aleksandra Bykova , Maria Serova , Maria Chashkina , et al Added: 1 year ago

Cardiovascular Renal Metabolic

Heart Failure
Effects of GLP-1 Receptor Agonists in Heart Failure Patients
Author(s): Anastasia Shchendrygina , Amina Rakisheva , Ilya Giverts , et al Added: 1 year ago

Heart Failure
Understanding the Role of GLP-1 RAs in the Treatment of HF
Author(s): Giovanni Battista Bonfioli , Matteo Pagnesi , Daniela Tomasoni , et al Added: 3 months ago

Cardiovascular Renal Metabolic
EASD 25: EMPIRE-PREVENT: Metabolic Effects of Empagliflozin in Patients at Risk of Heart Failure
Author(s): Camilla Andersen Added: 1 month ago
EASD Congress 2025 - Dr Camilla Andersen (The University of Western Australia, Perth, AU) joins us to discuss findings from the EMPIRE-PREVENT: Metabolic study, investigating the metabolic effects of empagliflozin in elderly and obese patients at high risk of developing heart failure (HF).This randomized controlled trial evaluated 165 patients aged 60–84 years with obesity (BMI >28kg/m²) and… View more

Cardiovascular Renal Metabolic

Demographic
EASD 23: Efinopegdutide in NAFLD & T2D patients
Author(s): Samuel S Engel Added: 2 years ago
EASD 2023 — In this short interview, Dr Samuel S Engel (Associate Vice President at Merck) discusses a study investigating the effectiveness and safety of efinopegdutide (MK-6024) in patients with nonalcoholic fatty liver disease and type 2 diabetes (NCT04944992).The phase IIa study randomized 145 participants (efinopegdutide, n = 72; semaglutide, n = 73). The majority (55.2%) of participants… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Dirk Müller-Wieland
Research Area(s) / Expertise: Job title: Professor of Endocrinology, Metabolism and Diabetes
Prof Dirk Müller-Wieland is a specialist in endocrinology and diabetology at University Hospital Aachen, Department of Medical Sciences (Aachen, DE). He leads the Cardiometric Prevention Working Group and the Clinical Study Center. His research and clinical interests focus on gene regulation, lipid metabolism, fat distribution, insulin resistance and cardiovascular risk.He studied medicine in… View more
Research Area(s) / Expertise: Job title: Professor, Obesity and Stress Hormone Research
Prof Liesbeth van Rossum, MD PhD, is internist-endocrinologist and professor in the field of obesity and stress hormone research at the Erasmus University Medical Center in Rotterdam, Netherlands. Sheis also co-founder of the Obesity Center CGG, an internationally recognised academic centre of obesity management.Prof Van Rossum holds various societal and board positions, amongst the European lead… View more
John Sliberbauer
John Silberbauer is a Consultant Cardiologist and Electrophysiologist working at the Sussex Cardiac Centre in Brighton. He has a special interest in ventricular arrhythmia ablation and enjoys teaching and research within the field. He undertook a 2-year VT fellowship under the tutelage of Dr Paolo Della Bella in Milan and has pioneered the Coronary Vein Exit and CO2 Insufflation technique for… View more